Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
TLDR
In this article, the authors reviewed the clinical features of myeloproliferative neoplasms (MPNs) patients with COVID-19 and suggested guidance for treatment, which is associated with a high rate of respiratory failure, thromboembolism, bleeding, and death.Abstract:
Purpose of review Coronavirus disease 2019 (COVID-19) is associated with a high rate of respiratory failure, thromboembolism, bleeding, and death. Patients with myeloproliferative neoplasms (MPNs) are prone to both thrombosis and bleeding, calling for special care during COVID-19. We reviewed the clinical features of MPN patients with COVID-19, suggesting guidance for treatment. Recent findings One study by the European LeukemiaNet collected 175 MPN patients with COVID-19 during the first wave of the pandemic, from February to May 2020. Patients with primary myelofibrosis (PMF) were at higher risk of mortality (48%) in comparison with essential thrombocythemia (ET) (25%) and polycythemia vera (19%); the risk of death was higher in those patients who abruptly discontinued ruxolitinib. In patients followed at home, in regular wards, or in ICU, the thrombosis rate was 1.0%, 2.8%, and 18.4%, respectively. Independent risk factors for thrombosis were ET phenotype, transfer to ICU, and neutrophil/lymphocyte ratio; major bleeding occurred in 4.3% of patients, particularly those with PMF. MPN patients with non-severe COVID-19 treated at home should continue their primary or secondary antithrombotic prophylaxis with aspirin or oral anticoagulants. In the case of hospitalization, patients assuming aspirin should add low molecular weight heparin (LMWH) at standard doses. In contrast, LMWH at intermediate/therapeutic doses should replace oral anticoagulants prescribed for atrial fibrillation or previous venous thromboembolism. Intermediate/high doses of LMWH can also be considered in ICU patients with ET, particularly in the case of a rapid decline in the number of platelets and progressive respiratory failure.read more
Citations
More filters
Journal ArticleDOI
Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
TL;DR: A comprehensive overview of the current knowledge on JAK inhibitors' effects on immune cells as well as their clinical consequences particularly with regards to infectious complications is provided in this article, where the authors provide a comprehensive overview.
Journal ArticleDOI
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Nicola Polverelli,Juan Carlos Hernández-Boluda,Tomasz Czerw,Tiziano Barbui,Mariella D'Adda,H. Joachim Deeg,Markus Ditschkowski,Claire N. Harrison,Nicolaus Kröger,Ruben A. Mesa,Francesco Passamonti,Francesca Palandri,Naveen Pemmaraju,Uday R. Popat,Damiano Rondelli,Alessandro M. Vannucchi,Srdan Verstovsek,Marie Robin,Antonio Colecchia,Luigi Grazioli,Enrico Damiani,Domenico Russo,Jessica L. Brady,David Patch,Sławomir Blamek,Gandhi Damaj,Patrick Hayden,Donal P. McLornan,Ibrahim Yakoub-Agha +28 more
TL;DR: In this article , a group of haematologists, transplantation physicians, gastroenterologists, surgeons, radiotherapists, and radiologists with experience in the treatment of myelofibrosis contributed to a shared position statement on splenomegaly.
Journal ArticleDOI
Treatment and Clinical Endpoints in Polycythemia Vera: Seeking the Best Obtainable Version of the Truth.
TL;DR: The challenges of addressing data gaps and outstanding questions in the emerging treatment landscape of PV are highlighted, as well as an expanding portfolio of active drugs.
Journal ArticleDOI
Covid-19 in patients with myeloproliferative neoplasms: the risk of thromboembolic events and current options for antithrombotic prophylaxis
TL;DR: A literature review of the presently available data on the risk of thromboembolic events and current options for antithrombotic prophylaxis in patients with myeloproliferative neoplasms (MPN) patients with concomitant coronavirus disease 2019 (COVID-19) is provided in this article .
References
More filters
Journal ArticleDOI
Endothelial cell infection and endotheliitis in COVID-19.
Zsuzsanna Varga,Andreas J. Flammer,Peter Steiger,Martina Haberecker,Rea Andermatt,Annelies S. Zinkernagel,Mandeep R. Mehra,Reto A. Schuepbach,Frank Ruschitzka,Holger Moch +9 more
TL;DR: The vascular endothelium is an active paracrine, endocrine, and Endothelial cell infection and endotheliitis in COVID-19 and recruitment of immune cells can result in widespread endothelial dysfunction associated with apoptosis.
Journal ArticleDOI
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Frederikus A. Klok,Marieke J. H. A. Kruip,N.J.M. van der Meer,M.S. Arbous,Diederik Gommers,K.M. Kant,F H J Kaptein,J. van Paassen,M A M Stals,Menno V. Huisman,Henrik Endeman +10 more
TL;DR: The findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophYLaxis towards high-prophylactic doses, even in the absence of randomized evidence.
Journal ArticleDOI
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.
TL;DR: Since then, the number of cases identified in Italy has rapidly increased, mainly in northern Italy, but all regions of the country have reported having patients with COVID-19, and Italy now has the second largest number of CO VID-19 cases and also has a very high case-fatality rate.
Journal ArticleDOI
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.
TL;DR: Three months ago, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) broke out in Wuhan, China, and spread rapidly around the world.
Journal ArticleDOI
Multiorgan and Renal Tropism of SARS-CoV-2.
Victor G. Puelles,Marc Lütgehetmann,Maja T. Lindenmeyer,Jan Sperhake,Milagros N. Wong,Lena Allweiss,Silvia Chilla,Axel Heinemann,Nicola Wanner,Shuya Liu,Fabian Braun,Shun Lu,Susanne Pfefferle,Ann Sophie Schröder,Carolin Edler,Oliver Gross,Markus Glatzel,Dominic Wichmann,Thorsten Wiech,Stefan Kluge,Klaus Pueschel,Martin Aepfelbacher,Tobias B. Huber +22 more
TL;DR: In this autopsy series, the authors found that SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart, liver, and brai...